alpha GPC -- Glycerylphosphorylcholine * Supports Cognitive Function
|Glycerylphosphorylcholine -- Supports Cognitive Function in AD ...||Darrell Miller||05/24/05|
May 24, 2005 09:52 AM
Author: Darrell Miller (firstname.lastname@example.org)
Subject: Glycerylphosphorylcholine -- Supports Cognitive Function in AD ...
Cognitive Improvement in Mild to Moderate Alzheimer's Dementia After Treatment with the Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Maria De Jesus Moreno Moreno, MD Instituto Nacional de la Senectud, Mexico City, Mexico
This study assessed the efficacy and tolerability of the cholinergic precursor choline alfoscerate (CA) in the treatment of cognitive impairment due to mild to moderate AD (Alzheimer's disease).
in both men and woman they consistently improved after 90 and 180 days versus baseline with adiministration of GPC three times a day, whereas in the placebo group they remained unchanged or worsened. Statistically significant differences were observed between treatments after 90 and 180 days.
Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction, Science. 1982;217:408-414. 2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: Dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449. 3. Hofman A, Rocca WA, Brayne C, et al, for the European Prevalence Research Group. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int d Epidemiol. 1991;20:736-748. 4. Blackwood W, Corsellis JAN, eds. Greenfield's Neuropathology. 3rd ed. London: Arnold; 1976. 5. Geldmacher DS. Cost-effective recognition and diagnosis of dementia. 5emin Neurol. 2002;22:63-70. 6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459. 7. Perry EK. The cholinergic hypothesis--ten years on. Br Med Bull. 1986;42:63-69. 8. Giacobini E. From molecular structure to Alzheimer therapy. Jpn d Pharmacol. 1997;74:225-241. 9. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int. 1998;32:413-419. 10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol. 1982;37:4-9. 11. Davis E, Emmerling MR, Jaen JC, et al. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993;7:41-83. 12. Amenta E Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropiate approaches? Mech Ageing Dev. 2001;122:2025-2040. 13. Sigala S, Imperato A, Rizzonelli P, et al. k-Alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eurd Pharmacol. 1992;211:351-358. 14. Govoni S, Battaini E Lucchi L, et al. Effects of alpha-glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]. Basi Raz Ter. 1991;21:75-78. 15. Canonico PL, Nicoletti F, Scapagnini U. Neurochemical and behavioral effects of alpha-glycerylphosphorylcholine [in Italian]. Basi Raz Te~ 1990;20: 53-54. 191 CLINICAL THERAPEUTICS ® 16. Parnetti L, Amenta E Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev. 2001;122:2041-2055. 17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29:185-198. 18. Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330-341. 19. Frattola L, Piolti R, Bassi S, et al. Multicenter clinical comparison of the effects of choline alphoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curt Ther Res Clin Exp. 1991;49:683-693. 20. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-c~-glycerylphosphorylcholine. Curt Ther Res Clin Exp. 1992;52:741-75l. 21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: APA; 1994. 22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. 23. Folstein ME Folstein SE. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. 24. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. 25. Hamilton M. A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-62. 26. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Clin Psych& 1967;6:278-296. 27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry. 1984;141:1356-1364. 28. Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139. 29. National Institute of Mental Health. Clinical global impressions. In: Guy W, ed. ECDEU Assessment for Psychopharmacology. Revised edition. Rockville, Md: National Institute of Mental Health; 1976:217-222. 30. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry. 1999;174:476-479. 31. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169. 32. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991. 192 M. Moreno 33. Lindstrom MJ, Bates DM. Newton-Rapshon algorithms for linear-mixed effects models for repeated measure data. J Am Stat Assoc. 1998;83:1014-1022. 34. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711. 35. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303. 36. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158:1021-1031. 37. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and the safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65. 38. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318: 633-638. 39. Amenta E Bronzetti E, Del Valle M, Vega JA. Effects of alpha-glycerylphosphorylcholine in neuroanatomy of aging brain in experimental animals [in Italian]. Basi Raz Te~: 1990;20:31-38. Address correspondence to: Scientific Department, Italfarmaco SpA, via dei Lavoratori 54, 20092 Cinisello Balsamo, Milan, Italy.